Reviva Pharmaceuticals (NASDAQ:RVPH), a clinical-stage biotechnology company specializing in treatments for central nervous system and respiratory diseases, issued its second quarter results on August 14, 2025. The highlight of the release was the completion of key clinical studies for its lead drug candidate, brilaroxazine, marking a significant milestone on the path toward regulatory submission. The company reported a net loss of $6.1 million, or $(0.12) per share (GAAP), Revenue remained at zero, consistent with its precommercial status. Operating costs declined compared to the prior-year period. The period demonstrates progress in Reviva's clinical strategy, but its limited cash balance and continued need for external funding remain prominent.

Source: Analyst estimates for the quarter provided by FactSet.

Reviva Pharmaceuticals is focused on developing novel therapies for central nervous system disorders, with a particular emphasis on schizophrenia and related conditions. Its lead candidate, brilaroxazine, is an oral drug under development for several psychiatric and respiratory diseases, such as schizophrenia, bipolar disorder, and pulmonary arterial hypertension.

Continue reading

Source Fool.com